



## SPEAKER PROFILES

17 February

**Synchronous tumours: the chemotherapy challenge for the modern oncologist**

**Emma Seaford**



Emma Seaford is a training paediatric oncologist based at the Bristol Royal Hospital for Children. She is currently undertaking a Clinical Trials Fellowship at the UK's largest Paediatric Clinical Trials Unit in Birmingham (Cancer Research UK Clinical Trials Unit) under the supervision of Professor Pamela Kearns. Her professional interests include B-NHL and early phase clinical trial development which she has successfully combined with an interest in travel. In 2013-2014 she spent a year working in rural Uganda delivering a clinical study aiming to improve cure rates and care for children with Burkitt's lymphoma. In 2017 she relocated to Basel, Switzerland, to gain first-hand experience of drug development from within the Roche pharmaceutical company during a one year Clinical Research Fellowship. Back in the UK she is currently dedicated to the development of Glo-BNHL, an international Platform Study designed to efficiently assess multiple prioritised novel agents in paediatric patients with relapsed and refractory B-NHL. She hopes to enjoy a long career as a Paediatric Oncologist working with many people across many countries.

**Meriel Jenney**



Professor Meriel Jenney has been a Consultant in Paediatric Oncology at the Children's Hospital for Wales for over 25 years and is Assistant Medical Director for Cancer Services (adult and paediatric) at Cardiff and Vale University Health Board.

She trained in Sheffield and Manchester in the UK and was also awarded a Harkness Fellowship to study in the US where she was based at the University of Minneapolis, Minnesota and studied this impact of cancer in childhood cancer on quality of life.

Her main research interests are: Rhabdomyosarcoma; the assessment of quality of life (QoL) of children with cancer; and the late effects of treatment for children with cancer. Prof Jenney is now Chief Investigator for the current international study in Rhabdomyosarcoma, the Frontline and Relapse study in Rhabdomyosarcoma (FaR-RMS).

She has previously served on the Board of the EpSSG and Chaired the National Cancer Research Institute (NCRI) Children's Cancer and Leukaemia Clinical Studies Group in the UK for 6 years (until 2019). She is on the steering group, trial management group and data monitoring committees for a number of national and international studies.